8-K Announcements
6Material company update
May 14, 2026·SEC
Material company update
May 11, 2026·SEC
Material company update
Apr 21, 2026·SEC
Inhibrx Biosciences, Inc.(INBX)Earnings, Financials & Key Ratios
INBX•NASDAQ
$100.75
Price updated Jul 7, 2026
AboutInhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.Show more
- Revenue$1M+550.0%
- EBITDA-$133M+59.7%
- Net Income-$140M-108.3%
- EPS (Diluted)-9.04-107.8%
- Gross Margin-91%+91.3%
- EBITDA Margin-10195.54%+93.8%
- Operating Margin-10386.54%+93.7%
- Net Margin-10773.46%-101.3%
- ROE-197.85%-110.4%
INBX Price & Volume
Inhibrx Biosciences, Inc. (INBX) stock price & volume — 10-year historical chart
Loading chart...
Pre-Commercial Oncology Pipeline Faces Capital Sustainability Risks
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical trial execution risk
Key Thesis Takeaways
- Inhibrx Biosciences remains a high-risk, pre-commercial biotechnology entity heavily reliant on its multivalent antibody pipeline to justify its current valuation.
- The company faces significant structural headwinds, characterized by persistent negative net margins and a rapidly depleting cash position that necessitates successful clinical trial outcomes to avoid further dilution.
- Investors should monitor the company's ability to manage its $24.7 million quarterly R&D burn rate against a backdrop of negative equity, which currently stands at -$21.0 million as of 2026Q1.
Verdict Logic
Negative: The company's reliance on non-recurring milestone payments and a $161.7 million cash balance that must support ongoing high-cost oncology trials suggests a high probability of future capital raises that could significantly dilute existing shareholders.
INBX Growth Metrics
Inhibrx Biosciences, Inc. (INBX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-36.72%
3 Years-15.98%
TTM550%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-107.56%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-107.2%
Return on Capital
10 Years-435.56%
5 Years-98.2%
3 Years-120.43%
Last Year-106.86%
INBX Recent Earnings
Inhibrx Biosciences, Inc. (INBX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 2/12 qtrs (100%)
Q2 2026Latest
May 14, 2026Metric
Actual
Est
EPS
$2.15+9.3%
$2.37
Rev
—
—
Q2 2026
Mar 19, 2026Metric
Actual
Est
EPS
$2.11-1.4%
$2.08
Rev
—
$1M
Q4 2025
Nov 14, 2025Metric
Actual
Est
EPS
$2.28-9.6%
$2.08
Rev
—
—
Q3 2025
Aug 13, 2025Metric
Actual
Est
EPS
$1.85+36.6%
$2.92
Rev
$1M
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 14, 2026 | $2.15vs $2.37+9.3% | — |
| Q2 2026 | Mar 19, 2026 | $2.11vs $2.08-1.4% | —vs $1M |
| Q4 2025 | Nov 14, 2025 | $2.28vs $2.08-9.6% | — |
| Q3 2025 | Aug 13, 2025 | $1.85vs $2.92+36.6% | $1M |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Inhibrx Biosciences, Inc. (INBX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $100.75 | $1.48B | -11.14 | 550% | -10773.46% | -197.85% | — | |
| $40.09 | $8.23B | -14.47 | — | — | -68.16% | — | |
| $27.67 | $3.46B | -212.85 | 91.34% | -0.57% | -1.41% | — | |
| $119.24 | $9.74B | -32.31 | -16.72% | -612.17% | -25.02% | — | |
| $323.95 | $9.36B | -24.03 | -100% | — | -43.02% | — | |
| $53.52 | $8.19B | 19.32 | 87.32% | 65.95% | 87.36% | — |
Compare INBX vs Peers
Inhibrx Biosciences, Inc. (INBX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
INBX SEC Filings & Documents
Inhibrx Biosciences, Inc. (INBX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when INBX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
INBX Frequently Asked Questions
Inhibrx Biosciences, Inc. (INBX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Inhibrx Biosciences, Inc.'s revenue?
Inhibrx Biosciences, Inc. (INBX) reported $1.3M in revenue for fiscal year 2025. This represents a 81% decrease from $6.7M in 2016.
How fast is Inhibrx Biosciences, Inc. growing?
Inhibrx Biosciences, Inc. (INBX) grew revenue by 550.0% over the past year. This is strong growth.
Is INBX profitable?
Inhibrx Biosciences, Inc. (INBX) reported a net loss of $130.2M for fiscal year 2025.
Dividend & Returns
What is INBX's return on equity?
Inhibrx Biosciences, Inc. (INBX) has a return on equity (ROE) of -197.8%. Negative ROE indicates the company is unprofitable.
What is Inhibrx Biosciences, Inc.'s free cash flow?
Inhibrx Biosciences, Inc. (INBX) had negative free cash flow of $131.9M in fiscal year 2025, likely due to heavy capital investments.